Oncology

Researchers from King’s College London and The Institute of Cancer Research, London, have performed a deep dive into the different immune markers within tumour tissue and blood samples of early breast cancer patients whose cancer failed to respond to chemotherapy given to them prior to surgery. The research gives insight into the function of immune […]

News round-up for 3-7 October by DDW Digital Content Editor Diana Spencer This week has brought new trial results and regulatory approvals shedding light and bringing hope into therapy areas of unmet need. The University of Birmingham and King’s College London have furthered our understanding of difficult to treat cancers, while Janssen has revealed encouraging results […]

Earlier this year, Cancer Research UK (CRUK) launched its innovation engine, Cancer Research Horizons, to streamline drug discovery through the combination of its commercial and therapeutics teams. Reece Armstrong sits down with Cancer Research Horizons’ Chief Business Officer, Tony Hickson and CEO of its Therapeutics division, Hamish Ryder, to learn about the organisation’s goals.  RA: […]

The University of Birmingham has published the results of a study undertaken in head and neck squamous cell carcinoma (HNSCC) by liquid biopsy company ANGLE, which characterised the epithelial-mesenchymal transition (EMT) status of circulating tumour cells (CTCs).   EMT is clinically significant due to its role in tumour progression and invasion, the development of metastasis, metabolic […]

This week in drug discovery (26-30 September) News round-up by DDW Editor Reece Armstrong. An interesting week across the board for the pharma sector with the first biologic for severe asthma approved in the EU. Elsewhere researchers have discovered new ways of  identifying cancer cells and a manufacturing system could advance the development and production […]

New trial data has shown that using a patient’s own immune cells could be a powerful immunotherapy for metastatic melanoma, an aggressive skin cancer.  The TIL (tumour-infiltrating lymphocytes) trial compared T cell therapy to standard immunotherapy with the checkpoint inhibitor ipilimumab.  The results of the trial were presented at the 2022 annual congress of the […]

A new genetically engineered herpes virus has delivered a one-two punch against advanced cancers in initial findings from a Phase I trial. Researchers have found that RP2 – a modified version of the herpes simplex virus – showed signs of effectiveness in a quarter of patients with a range of advanced cancers. Patients on the […]

Scientists have discovered a type of breast cancer cell that is highly efficient in invading and colonising distant organs and slow their growth once there to evade therapies. This phenomenon then leads to later metastatic breast cancer in patients who have been cancer-free for years. According to a study published in Cell Reports, the breast […]

A new combination therapy could represent a significant advancement in the treatment of metastatic colorectal cancer. Findings from the SUNLIGHT trial have revealed that the combination of trifluridine/tipiracil plus bevacizumab showed a statistically significant improvement in overall survival compared to trifluridine/tipiracil alone. The Phase III clinical trial studied participants with refractory metastatic colorectal cancer (mCRC) […]

Professor Dr Cornelis (‘Kees’) Melief has been awarded the 2022 Pedro J Romero Service to JITC Award by the Society for Immunotherapy of Cancer (SITC).  The Award recognises individuals who have made immeasurable contributions and demonstrated outstanding commitment to the Journal for Immunotherapy of Cancer (JITC) and will be presented at the SITC’s 37th Annual […]